UK Clinical Trial Reforms Take Effect, Cutting Set-Up Times to 122 Days and Making Trial Registration a Legal Requirement for the First Time
The MHRA and HRA's largest regulatory overhaul in 20 years went live April 28, introducing notifiable trials, a 14-day automatic-approval modification route, and mandatory transparency for UK studies.
Overview
The United Kingdom’s biggest clinical-trial regulatory overhaul in more than 20 years came into force on 28 April 2026, ending a 12-month implementation period that began when the amending statutory instrument was signed into law in April 2025. The Medicines and Healthcare products Regulatory Agency (MHRA) and the Health Research Authority (HRA) jointly developed the package, which rewrites the rules first set out in the Medicines for Human Use (Clinical Trials) Regulations 2004.
At its core, the reform creates risk-proportionate review tracks for lower-risk studies, codifies a single Combined Review across regulators and ethics committees, and turns clinical-trial registration and results publication into legal requirements for the first time in the UK, according to the government’s launch announcement.
What We Know
Set-up times have already fallen. The MHRA and HRA report that combined safety and ethical review now averages 41 days, and overall study set-up times have dropped from 169 days to 122 days, per the gov.uk announcement. Health Innovation and Safety Minister Dr Zubir Ahmed described the launch as a “landmark moment” that will “make tangible difference for thousands waiting for treatments,” while MHRA Chief Executive Lawrence Tallon said the reforms would help make the UK “a more attractive, internationally competitive destination,” as the government release records.
Notifiable trials and Route B. A new “notifiable trials” category creates a fast-track route for lower-risk studies that meet specified safety conditions, allowing them to start without a full MHRA assessment provided ethics review is in place. A parallel “Route B” pathway covers substantial modifications: eligible changes are automatically approved unless concerns are raised within 14 calendar days. The Route B mechanism was piloted between October 2025 and March 2026 and processed applications in an average of 7 calendar days, with more than half of registrations coming from commercial sponsors, the gov.uk announcement notes.
Mandatory transparency. For the first time in the UK, sponsors are legally required to register medicines trials in a public registry, publish a summary of results within 12 months of completion, and offer participants a plain-language summary of findings, according to the government. The MHRA has framed the transparency push as part of an effort to lift participant engagement and broaden trial diversity, as set out in its own implementation blog.
Other changes. The regulations adopt the international Good Clinical Practice guideline ICH-GCP E6(R3), simplify consent arrangements for low-intervention studies, support the use of computer-model simulations and overseas safety data that meets UK standards, and replace “subject” with “participant” throughout the legislation, per the MHRA Inspectorate.
Industry Reaction
Legal and industry observers have welcomed the reforms while questioning whether faster paperwork alone can reverse the UK’s recent slide as a trials destination. Peter Rudd-Clarke, a partner at law firm Osborne Clarke, told Medscape that the reforms are “a direct response to concerns that the UK has been losing ground as a destination for research, particularly post-Brexit,” but cautioned that “competitiveness depends on more than regulation alone” and that “industry will be watching closely to see the impact,” Medscape reports. Gerard Hanratty of Browne Jacobson stressed that companies will need “clear, concise and pragmatic guidance” from regulators to operationalise the changes, the same Medscape report notes.
The context is the UK’s drift after Brexit, when the country fell outside the scope of the EU Clinical Trials Regulation that took effect in 2022. The new domestic framework is designed to close that gap and reposition the UK against EU member states and other major trial destinations, Medscape reports.
What We Don’t Know
It is too early to say how the headline timing claims will hold up at scale. The 122-day average reflects studies completed before the new framework’s full requirements took effect, and the 7-day Route B figure was generated under a pilot that drew motivated early adopters. Whether notifiable-trial criteria will absorb the volume of low-risk studies regulators expect — and whether ethics committees can keep pace once the MHRA step is bypassed — will only become visible in 2026 and 2027 application data.
The transparency mandates also raise enforcement questions. The regulations make registration and summary publication legal duties, but neither the gov.uk launch release nor the MHRA Inspectorate guidance details penalties for non-compliance, leaving open how aggressively regulators will police late or missing results. The reforms come alongside parallel international moves to compress trial timelines, including the U.S. Food and Drug Administration’s real-time clinical trials pilot with AstraZeneca and Amgen, suggesting that regulatory acceleration is now a competitive front in itself rather than a UK-specific story.
Analysis
The reform’s quietest but most consequential change may be the legal status of trial transparency. Voluntary registration and results-reporting regimes have existed in the UK for years, but compliance has been uneven — particularly for academic-sponsored studies and trials that fail to meet endpoints. Putting registration and 12-month summary publication on a statutory footing aligns the UK with international transparency norms and, if enforced, will make the UK trial register a more reliable evidence base than it has been historically.
The risk-proportionate architecture — notifiable trials, Route B modifications, computer-model and overseas-data acceptance — is more conventional. It mirrors changes already in motion at the European Medicines Agency and the U.S. FDA, where regulators have spent the past several years trying to triage low-risk studies away from full review queues. The UK’s distinguishing feature is the speed of the pilot data: a 7-day Route B average is faster than equivalent pathways elsewhere, though the sample is small.
Whether any of this restores the UK’s position as a trials hub will depend on factors regulators do not control: NHS site capacity, recruitment infrastructure, and the broader cost of running studies in the UK relative to the EU and emerging markets. The MHRA and HRA have removed a layer of friction. The harder structural problems remain.